JPMorgan Calls Olema Oncology Sell-Off a 'Significant Overreaction'

JPMorgan has identified a buying opportunity in Olema Oncology (NASDAQ: OLMA), arguing that a recent sharp decline in the company's stock represents a "significant overreaction" by the market to a competitor's clinical trial results. The firm maintained its "Analyst Focus List" status for the small-cap biotech company.

Sell-Off on Competitor Data

Olema shares fell by approximately 25% after AstraZeneca announced its SERENA-4 study for the drug camizestrant missed statistical significance. AstraZeneca's trial evaluated a similar class of drug in first-line patients with ER-positive, HER2-negative advanced breast cancer.

According to JPMorgan, the market sell-off was unwarranted because investors were not pricing in any value for Olema's drug, palazestrant, in that first-line setting to begin with. The investment bank's analysis suggests the stock was already undervalued based solely on its potential in later-stage, or refractory, treatment settings.

Focus Shifts to Key Trial Data

Looking ahead, JPMorgan is focused on upcoming catalysts for Olema, primarily data from its pivotal Phase 3 OPERA-01 trial. Results from this study, which evaluates palazestrant as a monotherapy in second- and third-line metastatic breast cancer, are expected in the first quarter of 2027.

As a benchmark, the bank noted that palazestrant demonstrated promising progression-free survival in a prior Phase 1/2 study:

Ad

• 7.3 months in patients with an ESR1 mutation
• 5.5 months in wild-type patients

JPMorgan estimates that a positive outcome in the OPERA-01 trial could drive Olema shares to the mid-$20s range or higher. Conversely, a negative result presents a potential downside to the mid-single-digit per-share range.

Context and Analyst Sentiment

The renewed focus on Olema comes after the company announced it had completed enrollment for the OPERA-01 trial. Following that news, both Stifel and H.C. Wainwright lowered their price targets but maintained their Buy ratings on the stock, according to the source material.

Olema also recently reported a second-quarter loss of $0.61 per share, which missed analyst consensus estimates.